Press Release

Northbrook, Ill., July 7, 2026 /PRNewswire/ — Kalohexis, Inc., a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer cachexia, today announced the confidential submission of a draft Registration Statement on Form S-1 to the Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of its…

Northbrook, Ill., June 18, 2026 /PRNewswire/ — Kalohexis, Inc., a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer cachexia, today announced the appointment of Xuan Hui, B.Med., M.S., Ph.D., as Director of Corporate Strategy. Dr. Hui joins Kalohexis from Bank of America Securities,…

Data featured in oral presentation at ENDO 2026 show that dual MC3R/MC4R activation drives weight loss, limits rebound, and preserves lean mass in obese nonhuman primates 710GO, Kalohexis’ novel oral dual MC3R/MC4R agonist, is currently being evaluated in a Phase 1 clinical trial as a treatment for general obesity Northbrook, Ill., June 15, 2026 /PRNewswire/ —…

Dual Activation of MC3R and MC4R Drives Weight Loss and Reduces Food Intake in Male Primates with Obesity Northbrook, Ill., May 29, 2026 /PRNewswire/ — Kalohexis, a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer cachexia, today announced a publication in Nature Communications…

710GO is a next-generation, first-in-class oral dual MC3R/MC4R agonist designed to activate the melanocortin system to induce healthier, more durable weight loss Northbrook, Ill., May 28, 2026 /PRNewswire/ — Kalohexis, Inc., a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer cachexia, today announced…

Northbrook, Ill., April 17, 2026 /PRNewswire/ — Kalohexis, a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer cachexia, today announced a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22, 2026 in San Diego, CA.   At AACR 2026, a trials-in-progress poster will be presented by Endevica…

Northbrook, Ill., March 31, 2026 /PRNewswire/ — Kalohexis, a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer cachexia, today announced the appointment of Tony Mitchell as Chief Financial Officer. Mr. Mitchell brings more than two decades of accounting and finance leadership experience spanning…

Novel dual melanocortin-3 and -4 receptor (MC3R/MC4R) agonists with improved potency, selectivity, central exposure and cardiac safety profiles may unlock broad use in general obesity Northbrook, Ill., March 25, 2026 /PRNewswire/ — Kalohexis, a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer…

Kalohexis’ lead programs include 710GO, an oral dual melanocortin-3 and-4 receptor (MC3R/MC4R) agonist, a next-generation general obesity treatment; and mifomelatide, a dual MC3R/MC4R antagonist to prevent and treat cachexia in advanced cancers 710GO has shown healthier, more durable weight loss without lean body mass loss and other side effects common with GLP-1 receptor agonists Northbrook,…

NORTHBROOK, Ill., Oct. 2, 2025 /PRNewswire/ — Endevica Bio, a clinical-stage biotechnology company pioneering peptide therapeutics for metabolic diseases, announced a major scientific breakthrough that could redefine the therapeutic landscape for general obesity treatment. The company’s research demonstrates that co-agonism of the melanocortin-3 and melanocortin-4 receptors (MC3/4R) drives robust weight loss, unlocking the melanocortin system as a differentiated mechanism…